Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye

Completed · Phase 1

Conditions studied: Healthy Volunteers, Dry Eye Syndromes

In brief

This study will examine the safety, tolerability, and systemic pharmacokinetics of up to 3 different concentrations of AGN-232411 topical ophthalmic solution in healthy participants and participants with dry eye.

Key facts

Study ID

NCT02420730

Run by

Allergan

People needed

77

Starts

2015-06-01

Expected to finish

2016-03-01

Last updated by the study team

2016-07-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Stage 1
• Healthy participants.
• Stage 2 -Participants with the symptoms of dry eye disease.

You may not qualify if…

• Stage 1
• Known allergies or sensitivities to study medications, fluorescein, or lissamine green
• Stage 2
• Known allergies or sensitivities to study medications, fluorescein, or lissamine green
• Allergic ocular disease, ocular trauma, corneal erosions or ulcers, or uveitis within the previous 12 months
• History of any ocular surgery within the previous 12 months.

Where it is running

• Sall Research Center — Artesia, California, United States
• Lugene Eye Institute — Glendale, California, United States
• Montebello Medical Center, Inc. — Montebello, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.